Restore Vision
- Biotech or pharma, therapeutic R&D
- Academic, tech transfer
Restore Vision is a clinical-stage biotech company developing RV-001, the world’s first enzyme-based optogenetic gene therapy for inherited retinal diseases. Using a proprietary chimeric rhodopsin delivered to ON-bipolar cells, RV-001 mimics natural phototransduction and offers a gene-independent approach to restoring vision.